Pfizer COVID vaccine first to be approved in Australia

Paul Hayes

25/01/2021 11:10:52 AM

The TGA has granted provisional approval ahead of next month’s planned rollout, which will now start in late February due to production delays.

Pfizer/BioNTech vaccine vial
The Pfizer/BioNTech vaccine requires two doses at least 21 days apart. (Image: AAP)

The Therapeutic Goods Administration (TGA) has granted provisional approval for the Pfizer/BioNTech COVID-19 vaccine, clearing the way for its use in people aged 16 and older.
The approval comes a year to the day after Australia registered its first cases of COVID-19.
The vaccine, which requires two doses at least 21 days apart, is the first candidate to be approved for use in Australia.
Australia has purchased 10 million doses of the Pfizer/BioNTech vaccine – enough to vaccinate 20% of the population. The first phase of the vaccine rollout will be aimed at priority groups, including those over 70, adults with existing medical conditions, and Aboriginal and Torres Strait Islander people.
Prime Minister Scott Morrison has welcomed the news, though he indicated the country’s planned vaccine rollout will be slightly delayed.
‘We are more looking at late February now than mid-February because of the challenges that we have seen in the production and delivery for both AstraZeneca and Pfizer around the world,’ he said in a press conference.
‘Australia has taken the time, we have been watching and learning from the experience overseas and so we remain within the guardrails of the timeframe that we set a few weeks ago – but that will continue to come under challenge for events and circumstances that exist well beyond our shores.’
Several European countries have said supplies of the vaccine have fallen short of their orders.
The TGA’s decision is based on a rolling submission of data from Pfizer/BioNTech’s phase 3 clinical study, which demonstrated a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (first primary objective), and also in participants with and without prior SARS-CoV-2 infection (second primary objective), measured from seven days after the second dose.
‘The TGA’s processes are, I believe, the best in the world and we have ensured that they are thorough,’ Federal Health Minister Greg Hunt said.
‘This approval and the upcoming rollout of the vaccine will play an important part in our ability to manage the pandemic in 2021.’
Infectious diseases physician and Director of Infectious Diseases at Mater Health Associate Professor Paul Griffin told newsGP the approval is ‘great news.’
‘It was a challenging situation with many calls to bring approval forward and many people hesitant. Our regulator has clearly done its due diligence to make sure this is the right thing to do,’ he said.
‘To reflect on vaccine development, it’s been extraordinary that there have been so many good candidates going all the way through clinical trials and licensing in record time and without skipping any steps to make sure they’re safe and effective.’
Associate Professor Griffin said the effectiveness of the vaccines will be ‘very much dependent’ on uptake and encouraged Australians to be informed and propagate accurate information to ensure as many people as possible get vaccinated.
Dr Diego Silva from Sydney Health Ethics in the University of Sydney School of Public Health said the next step in Australia’s vaccine process is ‘for the Commonwealth and states to clearly and transparently articulate the plan for the distribution of the vaccines’.
‘In order to engender the public’s trust in the Pfizer and subsequent vaccines, including the trust of healthcare workers, it will be critical for the TGA to describe the pharmacovigilance system they’ll deploy to catch and analyse the negative side-effects that will occur as part of Australia’s rollout,’ he said.
‘As we saw last week with Norway and the deaths of those over the age of 80 who received the vaccine, the ability to quickly collate and analyse adverse events is critical for ensuring confidence in both the vaccine, as well as the policy and programmatic processes necessary to deliver the vaccine.’

Prime Minister Morrison was also keen to point out the news of an approved vaccine, while very encouraging, does not represent a ‘silver bullet’ that will allow people in Australia to stop being COVID-safe.
‘I have a simple message to Australia: thank you, Australia,’ he said. ‘Thank you that you have put us in a situation that is the envy of most countries in the world today. We intend to keep it that way. We intend to remain vigilant.
‘Once the vaccines start, that doesn’t mean you can jump on a plane to Bali the next day, that the masks or the quarantine arrangements disappear.
‘This will build, it will start at a small scale, but it is not a silver bullet.’
The Federal Government last week announced general practices interested in taking part in the vaccine rollout can submit expressions of interest (EOI).
Federal Health Minister Greg Hunt said the Australian Government is seeking EOIs from all accredited general practices, with the eventual aim being to have more than 1000 distribution points spread across the country.
Log in below to join the conversation.

COVID Pfizer vaccine

newsGP weekly poll Should after-hours Medicare rebates extend to all-day Saturday?

newsGP weekly poll Should after-hours Medicare rebates extend to all-day Saturday?



Login to comment

Dr Kenneth William Hogan   26/01/2021 10:42:44 AM

Not much use for GPs who will not be receiving the 95% effective Pfizer vaccine. Seems the RACGP was not able to convince the government that GPs are in fact frontline health care workers even though we are the point of first contact for sick people. So GPs are not included in the stage 1a rollout. We are in the Stage 1b rollout and will receive the 60% effective Astra-Zeneca vaccine along with pharmacists, firemen and policemen.
Pathetic effort by the RACGP though I must say I am not surprised.
Only thing that surprises me is that the Pharmacy Guild did not get the pharmacists into stage 1a.
This is the latest failure on top of funding failures for stage 1b, the ECG item number rip off and the soon to be enforced new AHPRA CME requirements where the bureaucrats will have us spending 50% of our CME time doing useless and onerous box ticking exercises.
The RACGP really needs to lift its game with lobbying or else it be decimated with the emergence of CME homes,

Dr Kenneth William Hogan   26/01/2021 5:51:43 PM

The article gives a totally false report of the Pfizer vaccine rollout when stating 10 million doses have been purchased to cover 20% of the population. Only about 1.4 million doses of the 95% affective Pfizer vaccine are expected any time soon and are reserved for stage 1a roll out (GPs not included). Subsequent stages will use the 60% affective Astra Zeneca vaccine - check the EOI document. The 10 million Pfizer doses are likely just an option to buy. The government probably wants the vast majority of Aussies vaccinated with the Astra-Zeneca vaccine as the price is 10% of the Pfizer vaccine - save lots of money and get the political kudos of having offered everyone vaccination. The average joe will be oblivious that he has only 60% protection versus the 95% protection that could have been gained by waiting a little bit longer for more Pfizer vaccine and spending more money. Can't see 60% protection rapidly producing herd immunity, kick starting the economy or reopening borders.